Single dose denileukin diftitox does not enhance vaccine-induced T cell responses or effectively deplete Tregs in advanced melanoma: immune monitoring and clinical results of a randomized phase II trial

BACKGROUND: Depletion of CD25(+) Tregs improves anti-tumor immunity in preclinical models. Denileukin diftitox is a recombinant fusion protein of human IL-2 and diptheria toxin fragment that also can kill CD25(+) T cells. Prior clinical trials of denileukin diftitox suggested reduction of FoxP3(+) T...

Descripción completa

Detalles Bibliográficos
Autores principales: Luke, Jason J., Zha, Yuanyuan, Matijevich, Karen, Gajewski, Thomas F.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2016
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4915048/
https://www.ncbi.nlm.nih.gov/pubmed/27330808
http://dx.doi.org/10.1186/s40425-016-0140-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4915048/
https://www.ncbi.nlm.nih.gov/pubmed/27330808
http://dx.doi.org/10.1186/s40425-016-0140-2

Ejemplares similares